Foreign companies doing business in China have focused in recent days on the case of GlaxoSmithKline (“GSK”), the British multinational producer of pharmaceuticals, biologics, vaccines and consumer healthcare products headquartered in London. Articles to date, however, have been more descriptive than analytical and have focused more on the alleged acts and potential implications for the individuals allegedly involved and not as much on potential exposure for the corporate entities and those corporate officers who were not directly involved in actions violating PRC law. This article addresses those points while also placing the case in the broader context of China today.
Members-only access
To access the full resource, you must be a member. Already a member? Login to unlock.
Login
Not an ACC member?
Gain access to a comprehensive collection of global resources for in-house counsel
Sign up for a 30-day trial
The information in any resource collected in this virtual library should not be construed as legal advice or legal opinion on specific facts and should not be considered representative of the views of its authors, its sponsors, and/or ACC. These resources are not intended as a definitive statement on the subject addressed. Rather, they are intended to serve as a tool providing practical advice and references for the busy in-house practitioner and other readers.